As the winter flu season approaches, Moderna is pushing to secure FDA approval for its new vaccine, mFlusiva, designed to protect people aged 50 and older from the flu. The crucial step comes in the form of an FDA advisory committee meeting, where experts will scrutinize the efficacy and safety of the vaccine. If approved, mFlusiva could become a vital addition to the arsenal of flu-fighting options, potentially saving countless lives and reducing hospitalizations. The vaccine's development comes at a time when flu seasons have been particularly severe, with the elderly and vulnerable populations bearing the brunt of the disease.
Moderna is seeking Food and Drug Administration approval of its new shot, dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season.
